6 Biotech Stocks to Watch in 2019
Big news could cause these biotech stocks to Biotech’s biggest stories this year include trial data and FDA decisions for therapies targeting indications with a massive need for new treatment options, including blood disorders, genetic diseases, and Alzheimer’s Disease. Many companies could see share prices pop or drop based on fast-approaching news in these indications, but six companies could be particularly exciting for investors to keep tabs on from here. In this episode of the Motley Fool’s Industry Focus Healthcare, host Shannon Jones is joined by Motley Fool contributor Todd Campbell to discuss:
The approaching results for Biogen’s (NASDAQ: BIIB) Alzheimer’s disease moonshot;
Why European regulators could make this a big year for bluebird bio (NASDAQ: BLUE);
How targeting the cause of sickle-cell disease could pan out for Global Blood Therapeutics (NASDAQ: GBT);
A new peanut-allergy treatment is around the corner thanks to Aimmune Therapeutics (NASDAQ: AIMT)
Vertex Pharmaceuticals (NASDAQ: VRTX) big opportunity to significantly boost its addressable market;
The news that could transform Duchenne’s muscular dystrophy treatment and send Sarepta Therapeutics (NASDAQ: SRPT) revenue soaring.
Subscribe to The Motley Fool’s YouTube Channel:
Or, follow our Google+ page:
Inside The Motley Fool: Check out our Culture Blog!
Join our Facebook community:
Follow The Motley Fool on Twitter: